Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Swalduz

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Lung Cancer (Amsterdam, Netherlands)|July 24, 2024
Treatment sequences in EGFR mutant advanced NSCLCM Wespiser, A Swalduz, M Pérol
Revue Des Maladies Respiratoires|May 22, 2021
[NSCLC and new oncogenic mutations: Diagnosis and perspectives]C Basse, A Swalduz, A Mc Leer, et al.
Scientific Reports|March 4, 2026
Mutation type, tyrosine kinase function in normal cell and tyrosine kinase inhibitor activity in cancersH Vanacker, P A Cassier, A Dufresne, et al.
ESMO Open|January 4, 2025
Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancersJ-Y Blay, M Brahmi, A Dufresne, et al.
ESMO Open|November 28, 2024
Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN studyN Girard, F Guisier, A Swalduz, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2025
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci studyM Wislez, C Mascaux, J Cadranel, et al.
ESMO Open|January 30, 2021
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancerP Heudel, S Chabaud, D Perol, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Lung Cancer (Amsterdam, Netherlands)|July 24, 2024
Treatment sequences in EGFR mutant advanced NSCLCM Wespiser, A Swalduz, M Pérol
Revue Des Maladies Respiratoires|May 22, 2021
[NSCLC and new oncogenic mutations: Diagnosis and perspectives]C Basse, A Swalduz, A Mc Leer, et al.
Scientific Reports|March 4, 2026
Mutation type, tyrosine kinase function in normal cell and tyrosine kinase inhibitor activity in cancersH Vanacker, P A Cassier, A Dufresne, et al.
ESMO Open|January 4, 2025
Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancersJ-Y Blay, M Brahmi, A Dufresne, et al.
ESMO Open|November 28, 2024
Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN studyN Girard, F Guisier, A Swalduz, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2025
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci studyM Wislez, C Mascaux, J Cadranel, et al.
ESMO Open|January 30, 2021
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancerP Heudel, S Chabaud, D Perol, et al.
Pageof 1